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Abstract
Previous studies in the K14-HPV/E2 mouse model of cervical carcinogenesis demonstrated that infiltrating macro-
phages are the major source of matrix metalloproteinase 9 (MMP-9), a metalloprotease important for tumor angio-
genesis and progression. We observed increased expression of the macrophage chemoattractant, CCL2, and its
receptor, CCR2, concomitant with macrophage influx and MMP-9 expression. To study the role of CCL2-CCR2 sig-
naling in cervical tumorigenesis, we generated CCR2-deficient K14-HPV/E2 mice. Cervixes of CCR2-null mice con-
tained significantly fewer macrophages. Surprisingly, there was only a modest delay in time to progression from
dysplasia to carcinoma in the CCR2-deficient mice, and no difference in end-stage tumor incidence or burden.
Moreover, there was an unexpected persistence of MMP-9 activity, associated with increased abundance of
MMP-9+ neutrophils in tumors from CCR2-null mice. In vitro bioassays revealed that macrophages produce solu-
ble factor(s) that can suppress neutrophil dynamics, as evidenced by reduced chemotaxis in response to CXCL8,
and impaired invasion into three-dimensional tumor masses grown in vitro. Our data suggest a mechanism whereby
CCL2 attracts proangiogenic CCR2+ macrophages with the ancillary capability to limit infiltration by neutrophils. If
such tumor-promoting macrophages are suppressed, MMP-9+ neutrophils are then recruited, providing alternative
paracrine support for tumor angiogenesis and progression.
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Introduction
Cervical cancer is the second most common form of malignancy
among women worldwide [1]. The predominant risk factor for cervical
cancer is the presence of oncogene-encoding DNA from the human
papilloma virus types 16 and 18 (HPV16 and 18) and their high-risk
papillomavirus relatives, which are found in 95% of all human cervical
cancers [2]. A transgenic mouse model of this disease was developed by
expressing the early region genes from HPV16 under the expression of
the human keratin 14 promoter, restricting expression of the viral on-
cogenes to the basal squamous epithelium [3]. Female mice treated
with sustained, low-dose estrogen (K14-HPV/E2) synchronously de-
velop cervical intraepithelial neoplastic (CIN) lesions that progress into
cervical carcinomas, closely mimicking cervical cancer progression in
humans [4]. Other characteristic markers of cervical neoplasias, such
as increased blood vessel density, vascular endothelial growth factor
production, and matrix metalloproteinase 9 (MMP-9) activity, parallel
the human condition [5].
Previous studies have shown that high numbers of tumor-infiltrating
macrophages (TIMs) correlate with poor prognosis in various forms of
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cancer, suggesting a role for these cells in tumor progression [6]. Fur-
thermore, a number of studies have shown that TIMs express a broad
range of tumor-promoting factors [7], and drive tumor angiogenesis
and metastasis in a mouse mammary polyoma middle-T (MMTV-
PyMT) tumor model [8,9]. In K14-HPV/E2 mice, TIMs express
abundant MMP-9, a protease known to promote tumor angiogenesis
and growth [10].
Chemokines are a family of secreted proteins that induce cell sur-
vival and migration through specific G-coupled receptors [11]. CCL2
(MCP-1), acting through its only reported receptor, CCR2, induces
the migration and activation of monocytes [12], and it has been im-
plicated in the recruitment of TIMs and their expression of MMP-9 in
several tumor types [13–16]. In human cervical cancer, CCL2 is abun-
dantly expressed in the stroma and associated with macrophage infil-
tration [17]. Recent work by Zijlmans et al. [18] demonstrated that
the absence of CCL2 mRNA expression in human cervical cancer
specimens was associated with decreased macrophage infiltration and
vascular invasion as well as smaller tumor size and increased overall
survival. We therefore hypothesized that suppression of macrophage
recruitment to the neoplastic cervix would lead to reduced MMP-9
expression, consequent inhibition of angiogenesis, and impaired tumor
formation and growth.
Herein we report that CCL2 and CCR2 expression increases con-
cordant with TIM-mediated inflammation during cervical carcinogen-
esis in the K14-HPV/E2 model. However, when K14-HPV/E2 mice
were crossed with CCR2-null mice, the consequent reduction in TIM
numbers failed to alter tumor angiogenesis or growth, but rather re-
sulted in an increase in the number of tumor-infiltrating neutrophils
expressing MMP-9. These data suggest that neutrophils can, in some
circumstances, compensate for macrophage loss in tumors, serving to
similarly facilitate tumor progression.
Materials and Methods
Transgenic Mice
The generation of K14-HPV [4] and CCR2-deficient mice [19]
have been previously described. CCR2-null mice were backcrossed
for six generations with FVB/n mice, then crossed with the K14-
HPV mice to yield CCR2 heterozygous K14-HPV mice. These mice
were then bred to yield CCR2-deficient K14-HPV mice. For these
studies, 1-month-old CCR2-null, CCR2-heterozygous, and wild-
type K14-HPV16 female mice were subcutaneously implanted with
60-day slow-release 17β-estradiol pellets (0.05 mg; Innovative Re-
search, Sarasota, FL) at 1, 3, and 5 months of age (K14-HPV16/
E2) [20] and were maintained in accordance with the University of
California, San Francisco (UCSF) institutional guidelines governing
the care of laboratory mice.
Antibodies
The rabbit MMP-9 antibody was a kind gift from Dr. Z. Werb at
UCSF [21]. The monoclonal rat anti–Meca-32, CD11b, and GR-1
were purchased from BD Biosciences (San Diego, CA). CD68 anti-
body was ordered from Serotec (Raleigh, NC) and F4/80 antibody
and the PMN antibody, clone 7/4, were obtained from Cedarlane
Laboratories (Ontario, Canada). The rabbit anti-CSF1R was from
Chemicon (Waltham, MA), and the platelet-derived growth factor re-
ceptor (PDGFR) antibody was from eBioscience (San Diego, CA).
Rabbit antimyeloperoxidase was purchased from DAKO (Cambridge-
shire, UK). All secondary antibodies conjugated with either fluorescein
isothiocyanate (FITC), Rhodamine-X, or biotin were purchased from
Jackson ImmunoResearch (West Grove, PA).
Histology and Immunohistochemistry
Sections for both paraffin wax– and OCT-embedded frozen tu-
mors were cut/prepared, and the antibody dilutions used were as fol-
lows: Meca-32 (diluted 1:200), F4/80 (diluted 1:100), CD68
(diluted 1:500), CD11b (diluted 1:100), CSF1R (1:200), PMN (di-
luted 1:500), GR-1 (1:50), and MMP-9 (diluted 1:400) and staining
was carried out on frozen sections that had been blocked using 4%
normal donkey serum in PBS. For 7/4 staining, sections were treated
for 5 minutes with proteinase K (DAKO, Carpinteria, CA) before
blocking. Tumor spheroid sections were incubated with anti–human
myeloperoxidase for 30 minutes, otherwise all primary antibodies
were incubated for 1 hour at room temperature followed by appro-
priate biotinylated or fluorescently conjugated secondary antibodies
for 30 minutes at room temperature. Coverslips were then mounted
on fluorescently labeled tissue using Vectamount with DAPI (Vector
Laboratories). Fluorescent images were viewed with a 40×/0.75 air
objective (except for blood vessels which were viewed with a 20×/
0.50 air objective), collected using a microscope (AxioScope2 Plus;
Zeiss, Thornwood, NY) with a digital camera (CA742-95; Hamamatsu,
Bridgewater, NJ) and OpenLab software version 3.1.7 (Improvision,
Lexington, MA). Biotinylated antibodies were developed with the stan-
dard elite ABC kit (Vector Laboratories, Burlingame, CA) with fast
DAB (3′3′ diaminobenzidine tetrahydrochloride) (Sigma-Aldrich, St.
Louis, MO). Slides were then counterstained with 1% methyl green
and were dehydrated in isobutanol and 100% xylene before coverslips
were mounted in a mounting medium (Cytoseal 60; Fisher Scientific,
Pittsburgh, PA). Colorimetric images were acquired using Axioimager.
A1 bright field microscope, AxioCam MRc5, and Axiovision AC ver-
sion 4.3 (Zeiss) and were viewed through a 10×/0.45 or 40×/0.95 air
objective. Magnifications were further increased using Adobe Photo-
shop version 7.0. Tissues were stained with secondary antibodies as con-
trols, and background staining was minimal unless otherwise noted.
Tumor Evaluation
The characterization of tumor stages (based on hematoxylin and
eosin staining) was performed as previously reported [22].
FACS Analysis
Cell sorting was carried out as previously published [23], using
biotinylated- PDGFRα (eBioscience) with phycoerythrin-conjugated
avidin (BD Biosciences) and FITC-conjugated F4/80 and CD68
antibodies (Serotec).
Real-Time Quantitative Polymerase Chain Reaction Analysis
RNA was isolated from samples using the RNeasy Kit (Qiagen,
Valencia, CA) according to the manufacturer’s directions. One micro-
gram of RNA was denatured and primed at 65°C for 5 minutes with
3-μg random primers (Invitrogen, Carlsbad, CA) and then converted
to cDNA using M-MLV reverse transcriptase (Promega, Madison, WI)
in a final volume of 20 μl. For the sorted cell populations, the WT-
Ovation RNA Amplification Kit (NuGen, San Carlos, CA) was used
according to the manufacturer’s directions to obtain at least 1 μg
of cDNA for each sample. Real-time quantitative polymerase chain
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reaction analysis (qRT-PCR) was carried out at the UCSF cancer geno-
mics core using commercially available probes for CCL2 and CCR2
from Applied Biosystems (Foster City, CA).
Substrate Zymography
Tissues were processed and analyzed as previously described [24].
All cervical samples were isolated from 4-month-old K14-HPV/E2 or
CCR2-null K14-HPV/E2 mice. At least five samples were analyzed
per genotype. Ear tissue was isolated from 6-month-old K14-HPV
mice as a positive control. Recombinant MMP-9 was purchased from
Chemicon (Temecula, CA).
Monocyte Isolation
Human buffy coats were obtained from the National Blood Transfu-
sion Service in theUK. This was diluted 1 in 5 calcium andmagnesium-
free Hanks’s balanced salt solution (HBSS), and 10-ml aliquots were
added to 250 μl of RosetteSep (Stem Cell, London, UK) solution and
incubated for 20 minutes. Twenty milliliters of HBSS 2% FCS was
added to the blood mixture that was then overlaid onto Ficoil-Paque
Plus (Amersham Biosciences, Uppsala, Sweden) and centrifuged at
1200g for 20minutes. The monocyte layer was collected, washed twice,
and labeled with CellTracker blue (Molecular Probes, Paisley, UK), be-
fore coculturing with spheroids. Flow cytometry showed that <95% of
these were CD14+ monocytes.
Neutrophil Isolation
Human peripheral blood from healthy volunteers was treated with
an anticoagulant, 3.8% w/v sodium citrate solution (BDH/AnalaR,
Poole, UK), and then centrifuged at 400g for 20 minutes; the upper
serum layer was then removed. The remaining cells were diluted 50:50
with HBSS (BioWhittaker, Berk, UK), overlaid onto Ficoll-Paque Plus
(Amersham Biosciences), and centrifuged at 400g for 40 minutes. The
neutrophil/erythrocyte layer was collected and subjected to hypertonic
lysis to remove erythrocytes. The remaining neutrophils were washed
and routinely found to be more than 95% viable.
In Vitro Neutrophil Migration Assay
Human monocytes or the human breast tumor cell line, T47D,
cells were seeded at 30,000 cells/well in 100 μl of Dulbecco’s mod-
ified Eagle’s medium containing 1% FCS in a 96-well plate for
4 hours and washed; adherent cells were then incubated for 24 hours
(the control medium was incubated for the same period without ei-
ther cell type). Supernatants were then collected, sterile-filtered, sup-
plemented with or without 10 nM CXCL8, and added to the lower
wells of a 48-well microchemotaxis chamber. A polycarbonate mem-
brane with 3-μm pores was placed on top of the chamber and 50 μl
of 1 × 106 neutrophils/ml in Dulbecco’s modified Eagle’s medium con-
taining 1% FCS was added to the upper wells for 1 hour at 37°C.
The number of neutrophils in the lower chamber was then quantified
by flow cytometry using CellQuest software (BD Biosciences, San
Jose, CA).
Monocyte/neutrophil Infiltration Into Tumor Spheroids
Human tumor spheroids were generated by seeding 5000 human
tumor (HeLa cervical cancer) cells in 100 μl of culture medium in
each well of an agarose-coated 96-well plate and were incubated at
37°C, 5% CO2 for 7 to 8 days. Before infiltration with leukocytes,
spheroids were cultured overnight in a 96-well plate with Minimal
Essential Medium with Earl’s salts (MEME), to stimulate intercel-
lular adhesion molecule 1 expression (and thus facilitate monocyte/
neutrophil adhesion and infiltration). Either 6 × 105 neutrophils/ml
(prelabeled with cell tracker red) or monocytes (prelabeled with cell
tracker blue) in serum-free MEME were added to each well and left
for 5 (neutrophils) or 24 hours (monocytes) at 37°C in a 5% CO2
incubator. Spheroids were then removed, washed twice in serum-free
MEME, and resuspended in 100 μl of serum-free MEME. Spheroids
infiltrated with monocytes were cultured for a further 5 hours with
the same concentration of freshly isolated neutrophils (again labeled
red), whereas spheroids infiltrated with neutrophils were cocultured
with freshly isolated monocytes (labeled blue) for a further 24 hours.
A shorter period was used for neutrophil cocultures than those
involving monocyte as they are known to be more labile in culture
than monocytes. Spheroids were then trypsinized in 0.25% trypsin
for 5 to 10 minutes at 37°C, washed, and analyzed by flow cytometry
to estimate the proportion of neutrophils, monocytes, and/or tumor
cells. In parallel cultures, spheroids were fixed with 10% buffered
formalin for 1 hour and were then embedded in a solution of molten
1.5% agarose and 4% formaldehyde (BDH/Merck, Poole, UK),
machine-processed (TP1020; Leica, Wetzler, Germany), and em-
bedded in paraffin wax. Neutrophils and/or monocytes were identi-
fied in sections of tumor spheroids by staining for myeloperoxidase.
Statistical Analysis
F4/80, CD68, CSF1R, PMN, and MMP-9 expressions were de-
termined by counting the staining per field using a custom Adobe
Photoshop Plug-in. At least five fields from each slide (mouse) were
measured with at least four mice for each group and an average/field
determined. These averages, as well as tumor volume, were compared
by nonparametric analysis of variance using InStat Software (Graph-
Pad, San Diego, CA). A chi-square analysis was used to evaluate
tumor incidence. In the cell migration assays, differences between
treatments groups were analyzed using the nonparametric Mann-
Whitney U test.
Results
CCL2 and CCR2 Are Upregulated in the K14-HPV/E2 Mouse
Model of Cervical Carcinoma
To assess the expression of CCL2 ligand and CCR2 receptor during
cervical carcinogenesis, real-time quantitative RT-PCR analysis was
performed on cervical tissues from normal (FVB/n) and dysplastic
(3 months old) K14-HPV/E2 mice. CCL2 expression was prominently
upregulated at this time point (i.e., 2 months after carcinogenesis
was initiated with sustained estrogen), when macrophage infiltration
of CIN 1/2 lesions becomes prevalent (Figure 1A). Likewise, CCR2
exhibited increased expression at this early stage of neoplastic progres-
sion concomitant with macrophage recruitment into tumors (Fig-
ure 1B). In an effort to determine which population of cells was
producing the ligand and receptor, cell sorting was performed. A single
cell suspension from 3-month-old cervixes was sorted into PDGFα+F4/
80−CD68− (fibroblasts), F4/80+CD68+ macrophages, and other un-
stained cells (a mixed-cell population of epithelial cells, other inflam-
matory cells, and endothelial cells). The RNA from these populations
was amplified, and qRT-PCR was used to analyze CCL2 expression.
Both the fibroblast and mixed-cell populations expressed CCL2 at
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low/negligible levels compared to macrophages. CCR2, as expected, was
predominantly expressed by the F4/80+CD68+ population in tumors
(data not shown).
Effect of CCR2 Deficiency on Tumor Progression
CCR2-deficient mice, originally described by Boring et al. [19], were
backcrossed into the FVB/n background for six generations and then
crossed with the K14-HPV16 transgenic mice to produce CCR2-null
HPV16 mice. We first analyzed the temporal appearance and progres-
sion of neoplastic lesions in HPV16/E2 female mice that lacked CCR2.
Surprisingly, neither was there a difference in the timing or histologic
character of the progressive CIN 1, 2, and 3 lesions (data not shown)
nor was there a difference in the incidence, tumor burden, or histologic
characteristics of cervical carcinomas (Figure 2A, and data not shown).
There was, however, a modest, albeit statistically significant, delay in
the timing of malignant progression. Overt cervical carcinomas were
detected in 60% of CCR2+/+ and CCR2+/− HPV16/E2 mice at
4 months, whereas there were no tumors detected in the CCR2−/− co-
hort at this time point. However, neoplastic lesions emerged in the
CCR2−/− mice a few weeks later, and after an additional month, the
incidence in all three cohorts was 100% (Figure 2B).
We next analyzed the angiogenic phenotype, motivated both by
our previous demonstration that MMP-9 expressing macrophages
were instrumental in promoting new blood vessel growth, and by
previous studies, particularly in hypoxic environments, that had
Figure 1. CCL2 and CCR2 are upregulated during K14-HPV/E2 tu-
morigenesis. RNA was isolated from the cervix of three estrogen-
treated nontransgenic FVB/n, and K14-HPV mice with dysplasia
(3 months) and real-time quantitative PCR used to determine (A)
CCL2 and (B) CCR2 expression. Additionally, RNA was isolated
from sorted fibroblasts (PDGFRα+), myeloid cells (F4/80+ and/or
CD68+), and the remaining unstained cells from a pool of 10 cer-
vixes from 3-month-old mice and qRT-PCR used to measure CCL2
expression in these populations (C). CCL2 expression was 0.07 in
the PDGFRα+ population. Expression levels were normalized to
those of the housekeeping gene GUS. Error bars show SEM.
Figure 2. Absence of CCR2 delays time-to-tumor onset but does not
affect tumor growth or incidence. Tumor incidence and burden were
assessed using hematoxylin and eosin–stained serial sections using
tissue collected frommice at 4 months, between 4.25 and 5months,
and more than 5 months of age. (A) Tumor volume (growth) was not
significantly different between any genotype at end stage. (B) Tumor
incidence was significantly delayed (P < .001) at the earliest stages
in CCR2-null K14-HPV/E2 mice. The n values for each group are dis-
played at the base of each bar.
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directly implicated CCL2 in inducing angiogenesis [25]. Blood vessel
morphology and density were assessed using immunofluorescence for
two markers, Meca-32 (Figure 3A) and CD31 (data not shown). Com-
parative evaluation of cervical tissue from 3-, 4-, 5-, and 6-month-old
CCR2-null and wild-type K14-HPV/E2 mice revealed no appreciable
difference in either vessel parameter (data not shown). Immunohisto-
chemistry for MMP-9 was also performed on tumor sections from
4-month old mice, which revealed only a small decrease in expression
in CCR2-deficient mice (Figure 3B). Because MMP-9 is synthesized as
a precursor molecule that must be cleaved to be activated, expression
does not always indicate activity. Therefore, nonquantitative gelatin zy-
mography was used to assess MMP-9 activity at the same time point.
Figure 3C demonstrates that there were comparable levels of active
MMP-9 protease in the cervix of both wild-type and CCR2-deficient
K14-HPV/E2 mice. Dysplastic skin from these mice, which were
shown to have elaborate MMP-9 activity [26], again showed little im-
pact of CCR2 deficiency on the levels of active protease. The above
results indicate that a sufficient level of MMP-9 is being produced
in the CCR2 knock-out mice to support tumor angiogenesis and
tumor progression. We therefore sought to assess the effect of CCR2
deficiency on the abundance of TIMs in this model, because one
explanation of our data would be that TIM infiltration persisted in
the absence of CCR2 deficiency.
CCR2 Deficiency Diminishes Macrophage
Recruitment and Activation
Because macrophage infiltration of the neoplastic lesions in the
cervix is prominent at 4 months of age in K14-HPV/E2 mice, this
time point was used to analyze macrophage recruitment in the ab-
sence of CCR2. Tissue sections were stained with antibodies against
F4/80 (a marker for mature macrophages) and CD68 (which labels
Figure 3. Effect of CCR2 deficiency on tumor angiogenesis and MMP-9 expression. (A) Immunohistochemical analysis of Meca-32 (Rho-
damine, red; endothelial cells) in tumor sections at 1-month intervals during tumorigenesis revealed no striking differences. E indicates
the epithelium; S, stroma. Nuclei are shown in blue by staining with DAPI; original magnification, ×200. (B) Tissue sections were
immunohistochemically stained with an antibody against MMP-9, and expression per field was quantified in the cervical stroma of
4-month-old K14-HPV/E2 and CCR2-null K14-HPV/E2 mice (P = .03). (C) Tissues were collected from mice at the same age, and non-
quantitative substrate zymography was performed to assess the presence of MMP activity.
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all monocytes/macrophages). Cervical intraepithelial neoplastic
lesions in K14-HPV/E2 mice were infiltrated with higher numbers
of macrophages than those in CCR2-null K14-HPV/E2 mice
(Figure 4A). The density of stained cells in the CCR2-deficient mice
was comparable to estrogen-treated nontransgenic mice (FVB/n/E2),
suggesting that only resident macrophages rather than inflammatory
macrophages were present (Figure 4A). Because CCL2 signaling has
been implicated in the synthesis and activation of MMP-9 in mono-
cytes [13], MMP-9 expression was also analyzed in these resident
macrophages. Notably, marked changes in expression patterns were
evident. In wild-type mice, MMP-9 was expressed almost exclusively
by F4/80+ macrophages, whereas in the CCR2-null mice, the fre-
quency of MMP-9 coexpression with F4/80 was markedly reduced
(Figure 4, B and C ). This difference suggested that an alternative cell
type might be supplying the comparable levels of MMP-9 detected in
the CCR2-null K14-HPV/E2 mice.
Neutrophils Are Abundant in the Tumor Stroma of
CCR2-Null K14/HPV/E2 Mice
Tumor-infiltrating neutrophils have been reported to express
MMP-9 in another mouse model of cancer, the RIP-Tag2 islet carci-
noma model [27]. Therefore, immunofluorescent analysis was carried
out using the monoclonal antibody clone 7/4, which recognizes a cell
surface antigen present on neutrophils (as well as a subset of mono-
cytes). Costaining of MMP-9 with 7/4 revealed that 7/4+ cells in
CCR2-null K14-HPV/E2 mice expressed MMP-9, whereas they
failed to do so in tumors in wild-type mice (Figure 5A).
The presence of MMP-9+ neutrophils in the macrophage-depleted
tumors of CCR2 deficient mice suggested a possible compensatory
mechanism in which MMP-9 is supplied by a different inflammatory
cell population. This hypothesis warranted further analysis. Because
the 7/4 monoclonal antibody is reported to label macrophages in ad-
dition to neutrophils [28], immunohistochemical staining with 7/4
was carried out in conjunction with hematoxylin and eosin staining
to assess the cell morphology of 7/4+ cells in tumors in wild-type and
CCR2-null K14-HPV/E2 mice. Many of the 7/4
+ cells in wild-type
lesions were identifiable as macrophages, as judged by their size and
the round appearance of their nuclei. In contrast, the 7/4+ cell pop-
ulation in tumors of CCR2-null K14-HPV/E2 mice had the typical
multilobed nucleus indicative of neutrophils (Figure 5B). Costaining
of these populations using an antibody for CSF1R (another marker
of cells of the monocyte/macrophage lineage) showed colocalization
in the majority of 7/4+ cells in the CCR2+ wild-type mouse, confirm-
ing that these were, indeed, macrophages. Conversely, staining in tu-
mors in CCR2-null mice showed no expression of CSF1R by 7/4+
cells (Figure 5B). Quantitative analysis of the staining of these two
populations in tumors revealed that 7/4+, CSF1R+ macrophages were
abundant in wild-type, but rare in the CCR2-deficient K14-HPV/E2
mice, whereas 7/4+, CSF1R− neutrophils were prevalent in CCR2-
null and rare in the CCR2 wild-type K14-HPV/E2 mice (Figure 5C ).
We went on to further analyze the 7/4+ populations in both the
wild-type and CCR2-null mice. As expected, costaining with CD68
showed staining similar to CSF1R (Figure 6). Costaining with the
mature macrophage marker, F4/80, showed no colocalization with
7/4 in either tumor genotypes (Figure 6), indicating that the 7/4+,
CSF1R+ population consists of monocytes and/or relatively immature
macrophages. GR-1, a neutrophil marker, was coexpressed with 7/4 in
tumors in CCR2-deficient mice, whereas minimal coexpression was de-
tected in the cervix of wild-type HPV mice (Figure 6). Finally, CD11b/
Figure 4. CCR2 inhibition blocks macrophage recruitment to the
cervical stroma. (A) Immunohistochemical analysis of F4/80 and
CD68 was performed, and staining was quantified per field in non-
transgenic FVB/n and 4-month-old CCR2 wild-type, heterozygous,
and null K14-HPV/E2 mice. In all cases, there are significantly fewer
positively stained cells in the CCR2-null mice compared to wild-type
K14-HPV/E2 mice. There is no significant difference in expression
between nontransgenic and CCR2-deficient transgenic mice. (B)
Images of MMP-9 (FITC, green) colocalization with the macrophage
marker F4/80 (Rhodamine, red) in 4-month-old wild-type and CCR2-
null K14-HPV/E2 mice. Yellow indicates colocalization, and green ar-
rows indicate MMP-9+, F4/80− cells. Original magnification, ×400.
(C) % of all MMP-9 cells expressing F4/80.
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Mac-1, which is expressed at varying levels by neutrophils, monocytes,
macrophages, and other inflammatory cells, was expressed on all 7/4+
cells in the null mice. Notably, CD11b is upregulated on activated neu-
trophils. However, CD11b was expressed on only a portion of the 7/4+
cells in wild-type CCR2 cervical neoplasias, emphasizing the heteroge-
neity of this myeloid population (Figure 6).
Collectively, these data suggest an inflammatory leukocyte infiltrate in
the neoplastic cervix of wild-type mice composed of immature macro-
phages (7/4+, CSF1R+, F4/80−, MMP-9−), activated inflammatory
macrophages (7/4−, CSF1R+, F4/80+, MMP-9+), along with mature
and/or resident macrophages (7/4−, CSF1R+, F4/80+, MMP-9−), with
neutrophils being relatively rare. In contrast, the cervical neoplasias
in CCR2-deficient mice have abundant neutrophils (7/4+, GR-1+,
CSF1R−, F4/80−, MMP-9+), along with similar levels of resident
macrophages, but with comparatively few immature and inflamma-
tory macrophages.
Macrophages Inhibit Neutrophil Recruitment
We investigated two mechanisms by which the abundance of neu-
trophils in tumors in CCR2-null mice might be explained. One was
that, in the absence of macrophages, cervical tumors upregulate
neutrophil chemoattractants and/or survival factors, thus importing
a new source of MMP-9. Another was that signals emanating from
TIMs in wild-type mice normally block neutrophil recruitment and/
or survival, and that these inhibitory signals were therefore missing in
tumors in CCR2-deficient HPV/E2 mice.
In an effort to assess the first possibility, we audited a set of cyto-
kines and chemokines associated with neutrophil recruitment by
qRT-PCR of 4-month-old wild-type and CCR2-deficient cervical
tissue. There was no appreciable change in expression of CCL3,
CCL5, CXCL1, CXCL2, G-CSF, and IL-23 (data not shown). Only
one gene, GM-CSF, demonstrated upregulation of mRNA that would
be consistent with increased neutrophil inflammation in the CCR2-
null tissues; there was, however, no difference in GM-CSF expression
at the protein level as assessed by immunostaining (data not shown).
Thus, this survey did not implicate increased expression of neutrophil
chemoattractants as the basis for the neutrophil inflammation of cer-
vical neoplasias in CCR2-null mice.
To investigate the alternative hypothesis that infiltrating macro-
phages normally prevent neutrophil recruitment and/or inhibit their
survival, we employed two ex vivo cell migration assays. First, we used
a modified Boyden chamber chemotaxis assay to examine the effect
of monocyte-derived factors on neutrophil migration in response to
the well-characterized neutrophil chemoattractant, CXCL8. Medium
alone, medium containing recombinant human CXCL8, or medium
conditioned previously by human monocytes or another cell type (in
this case, the human tumor cell line, T47D) was placed in the lower
chamber of the assay device, with or without the addition of CXCL8.
Neutrophils isolated from human peripheral blood were then placed
in the upper chamber, separated from the lower one by a 3-μm-pore
membrane. After 1 hour, the number of neutrophils that had migrated
to the lower chamber was counted. CXCL8 induced a significant (P =
.01) increase in the number of neutrophils migrating across the filter
into the lower chamber. This CXCL8-dependent chemotaxis was ab-
lated by the addition of medium conditioned by monocytes but not
tumor cells with or without added CXCL8 (Figure 7A), indicating that
monocytes produce one or more soluble factors that inhibit neutrophil
migration in response to CXCL8.
Figure 5. Neutrophil expression colocalizes with MMP-9 in CCR2-
deficient mice. Immunohistochemistry was performed with MMP-9
and the neutrophil antibody clone 7/4 on tissues from 4-month-old
mice. (A) Representative images of MMP-9 (Rhodamine, red) colo-
calization with the 7/4 clone (FITC, green) in wild-type and CCR2-null
K14-HPV/E2 cervical tissues. (B) Hematoxylin and eosin staining
(original magnifications: ×100 for large panel and ×1000 for inset)
with the 7/4 clone shows that 7/4 is expressed on macrophages in
K14-HPV/E2 mice and on neutrophils in the CCR2-null counterparts.
Neutrophils can be clearly identified by morphology in the null mice
but were rare in the cervical stroma of wild-type mice. 7/4 staining
(FITC, green) of macrophages was further confirmed by colocaliza-
tion with the macrophage marker CSF1R (Rhodamine, red) only in
wild-type mice. Original magnification, ×400 for all fluorescent
images. (C) Staining for both 7/4 single-positive and 7/4 and CSF1R
double-positive populations was determined in both mouse geno-
types (P < .001).
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To better emulate events occurring within the tumor microenvi-
ronment, we also used a tumor spheroid model described by us pre-
viously [29], in which tumor cells seeded in nonadherent culture
dishes grow as spherical, three-dimensional tumor masses. Tumor
spheroids have previously been observed to elicit infiltration of both
monocytes and neutrophils by virtue of their release of various che-
mokines (including CCL2) [29]. Two human tumor cell lines, HeLa,
derived from a cervical carcinoma, which expresses the HPV-18
oncogenes, and A549, a lung carcinoma–derived cell line, were cul-
tured for 7 to 8 days under conditions that allow tumor spheroids of
700 to 800 μm in diameter to develop. These spheroids were then
preincubated overnight with CD14+ monocytes freshly isolated from
human peripheral blood, which resulted in the marked infiltration of
monocytes into the spheroids. Then the monocyte-infiltrated spheroids
were incubated for 5 hours with peripheral blood neutrophils. Spher-
oids were then enzymatically dispersed, the cells collected for flow
cytometry, and the number of spheroid-infiltrating neutrophils deter-
mined. There was a significant (P < .01) decrease in the number of
neutrophils present in spheroids following preincubation with mono-
cytes with both types of tumor cell spheroids (Figure 7B). Immunohis-
tochemistry for the enzyme myeloperoxidase, illustrating the infiltration
of neutrophils into tumor spheroids, is shown in Figure 7C. Tumor
spheroids derived from both lines showed the same ability to separately
recruit monocytes or neutrophils, indicating that the sequential addi-
tion of macrophages followed by neutrophils resulted in an active re-
striction of neutrophil infiltration that would otherwise occur.
Taken together, the two cell culture experiments indicate that
monocytes produce one or more factors that inhibit neutrophil infil-
tration into tumors. To determine if neutrophils could similarly in-
hibit macrophage recruitment, the same spheroid experiment was
carried out in the opposite order, using both human tumor cell lines.
Spheroids were preincubated with neutrophils for 5 hours, during
which time they infiltrated the spheroids, followed by an overnight
incubation with monocytes. Subsequent flow cytometric analysis re-
vealed no difference in the number of infiltrated monocytes, suggest-
ing that preexisting neutrophils are not able to inhibit monocyte
chemotaxis under these conditions (Figure W1).
Discussion
This study has investigated the hypothesis that macrophage in-
flammation of cervical neoplasias and cancers is mediated by signaling
of the CCL2-CCR2 chemokine circuit. Whereas the results show,
as expected, a reduced number of macrophages, there was an un-
expected persistence of MMP-9 levels in the tumors of mice, a sur-
prising result in light of clear evidence that TIMs are the major
source of this enzyme in cervical neoplasias in this model as well as
in humans [9,30]. Seeking an explanation for this dichotomy, we dis-
covered an alternative source of MMP-9 – neutrophils – in tumors in
CCR2-null mice. Seeking in turn to explain this increased infiltration
of MMP-9+ neutrophils, we assessed the expression of neutrophil
chemoattractants and survival factors, finding no obvious difference
between wild-type and CCR2-deficient tumors. In contrast, two
ex vivo bioassays involving human macrophages and neutrophils re-
vealed that macrophages were capable of suppressing neutrophil
chemotaxis and infiltration, but not vice versa, potentially providing
a rationale for the distinctive inflammatory cell dynamics in cervical
lesions of the CCR2-positive versus CCR2-null genotypes. These
observations, involving two distinctive human tumor-derived cell
lines, are certainly suggestive rather that definitive, but nevertheless
encourage the hypothesis that the capability of monocytes to inhibit
neutrophil infiltration may be operative in multiple tumor types, in-
cluding cervical carcinoma and lung.
Figure 6. Colocalization of 7/4+ cells with macrophage and neutrophil markers in the cervix. Tissue sections from both wild-type and
CCR2-deficient mice were stained with antibodies against CD11b, GR-1, CD68, and F4/80 (Rhodamine, red) and with the 7/4 clone (FITC,
green) to further characterize these cells as having neutrophil markers in CCR2-null mice and macrophage markers in wild-type mice.
Yellow arrows indicate coexpression. Original magnification, ×400.
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As previously mentioned, we were not able to identify changes in
chemokines associated with neutrophil recruitment. Instead, our in vitro
bioassays suggest an alternative explanation: in some tumor types,
macrophages can suppress neutrophil migration and/or persistence
by their release of one or more soluble factor(s). Infiltrating neutro-
phils are typically short-lived inside tissues (usually lasting only a few
hours), and thus accumulation of macrophages could quickly block
ongoing neutrophil chemotaxis and encourage the resolution of neu-
trophil inflammation. It has also been proposed that macrophages
influence neutrophil accumulation during inflammation through
phagocytosis of the apoptotic neutrophils [31], and may even induce
apoptosis in neutrophils directly [32]. For instance, Li et al. [33] found
that blocking CCL2 using a neutralizing antibody or a peptide antag-
onist of CCR2 resulted in a delayed clearance of apoptotic neutrophils
in a rat model of tubulointerstitial nephritis. Although we did not de-
tect an increase in neutrophil apoptosis in the stroma of tumors of
CCR2-deficient mice (data not shown), given the rapid kinetics of
apoptosis and the 6-month time-course of progression in this model,
we were not able to rule out macrophage-induced neutrophil apoptosis
as a factor in the differential abundance of neutrophils in wild-type
versus CCR2-deficient cervical neoplasias and cancers.
A similar capability of macrophages to influence the dynamics of
neutrophil infiltration and function has been implicated in other stud-
ies of inflammation in CCR2-null mice. One study reported persistent
neutrophils in the peritoneum up to 5 days after intraperitoneal injec-
tion of the proinflammatory agent thioglycollate in CCR2-null but not
wild-type mice [34]. In another study, granuloma formation following
zymosan A injection was found to be attenuated in CCR2-null mice,
with an atypical increase in neutrophils inside the granulomas [35].
CCR2-deficient mice infected with influenza virus were also found
to have increased alveolar neutrophils [36].
Altered neutrophil regulation has also been observed in CSF-1
mutant mice; CSF-1 is a major growth factor in the development,
proliferation, and survival of monocytes and macrophages [37].
CSF-1 mutant mice (csf1op/csf1op) are impaired in macrophage differ-
entiation and inflammatory phenotypes, as seen both in the context
of inflammation induced by bacterial infection [38] and mammary
carcinogenesis [7,8]. Notably, a persistence of infiltrating neutrophils
was observed in the livers of CSF-1 mutant mice following Listeria
monocytogenes infection [38]. Neutrophils are abundant in the context
of macrophage deficiency in the MMTV-PyMT, csf1op/csf1op model
of breast carcinogenesis (J.W. Pollard, personal communication).
In this case, however, the malignant phenotype is impaired by the
reduction in macrophage influx [39], indicating that neutrophils can-
not fully substitute for the macrophage effector functions, which in-
cludes supply of epidermal growth factor [40] and vascular
endothelial growth factor [8]. These differences highlight the poten-
tial for tissue-specific (and perhaps tumor type–specific) variations in
tumor-promoting inflammatory responses. Indeed, there are indica-
tions of heterogeneity in cervical cancers, given that reduced CCR2
Figure 7. Monocytes inhibit neutrophil migration and infiltration into human tumor spheroids in vitro. (A) Cell migration assays were
carried out using control, monocyte-conditioned medium (CM), or tumor cell CM spiked with the neutrophil chemoattractant CXCL8
as described in Materials and Methods. CXCL8 promoted neutrophil migration that was significantly ablated in the presence of mono-
cyte CM but not of tumor cell CM. (B) Human tumor (cervical; HeLa or lung; A549) spheroids were cocultured with either neutrophils
alone for 5 hours or monocytes for 16 hours followed by neutrophils for 5 hours. Spheroids were then washed and enzymatically di-
gested, and flow cytometry was used to quantify the number of infiltrating neutrophils. Significantly (P < .001) fewer neutrophils infil-
trated into spheroids when monocytes were already present in these structures than when they were absent. (C) Immunohistochemistry
using an antimyeloperoxidase antibody (brown; arrows) illustrates the presence of neutrophils in tumor spheroids following coculture.
This marker could detect both monocytes and neutrophils in HeLa spheroids when the latter were cocultured with each cell type alone.
However, there was no (cumulative) increase in MPO+ cell number when monocytes were allowed to infiltrate spheroids before their
culture with neutrophils (data not shown). N indicates the necrotic core at the center of spheroids. Scale bar, 150 μm.
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levels in one study correlated with a better prognosis [18]; whereas
other undefined variables may influence this correlation, on inference
is that neutrophil substitution was not pronounced or was ineffectual
in this patient population, possibilities that deserve further investiga-
tion in other human population studies.
Additionally, other functional studies in mouse models and correl-
ative/prognostic studies in human tumors have revealed complexity
and, indeed, a dichotomy in the effects of infiltrating macrophages
on tumor phenotypes. In many tumor types, macrophages promote
angiogenesis, tumor growth, and metastasis, and their presence corre-
lates with poor prognosis and survival [6]. In other tumor types, macro-
phages appear to inhibit such phenotypes, perhaps reflecting the effects
of an antigen-presenting macrophage involved in antitumor immune
responses. These conflicting correlations suggest the existence of distinct
macrophage populations genetically determined early in monocyte dif-
ferentiation and/or elicited by the local microenvironment. CCR2 ex-
pression, which has been attributed to inflammatory rather than
resident macrophages [41], may characterize a predetermined set of
macrophages that have proinflammatory and ultimately protumor
properties. Whereas these cells are recruited to sites of inflammation
through CCR2-CCL2 signaling, it seems likely that local factors in the
neoplastic microenvironment instruct these cells to mediate tumor-
promoting functions, including MMP-9 expression and activation.
The cervical microenvironment appears to reflect one class of organ-
specific tumors, in which macrophages are selectively recruited during
neoplastic development, much as in the aforementioned model of
MMTV-PyMT breast cancer [8]. Another mouse model, of pancreatic
islet carcinoma, is characterized by early infiltration of MMP-9–
expressing neutrophils as well as two distinctive classes of MMP-9+
and MMP-9− macrophage [26,27]. Thus, the neoplastic microenvi-
ronment clearly governs the dynamics of proangiogenic leukocyte in-
filtration. Notably, macrophage inflammation is mild in the pancreatic
islet cancer model, in contrast to the cervix and breast tumor models,
where the macrophage influx is more pronounced. It could be that a
critical density of lesional macrophages is necessary to suppress the in-
flux and persistence of neutrophils.
A related issue involves the source in the cervical neoplasias of the
ligand for CCR2 that mediates macrophage recruitment. By using
FACS and qRT-PCR, we determined that the CCL2-producing cells
in the cervix are myeloid-derived cells recruited to the early neoplas-
tic microenvironment of the cervix through a yet unknown mecha-
nism, presumably a result of expressing the HPV oncogenes in the
epithelium. The recruitment of these CCL2-expressing cells appears
to be independent of CCR2, because there was no decrease in CCL2
expression in the cervix of CCR2-deficient HPV/E2 mice (data not
shown). The nature of these proinflammatory myeloid cells, and the
mechanism by which they are recruited to in turn recruit CCR2+
MMP-9+ macrophages that promote angiogenesis and tumorigenesis,
deserves future investigation.
In conclusion, this study has revealed a complex interplay between
tumor-infiltrating macrophages and neutrophils that contributes to neo-
plastic progression. The plasticity of leukocyte inflammation revealed in
this study, in which proangiogenic neutrophils replace the functions of
proangiogenic macrophages when the latter are suppressed, has poten-
tial therapeutic implications. If the recruitment of proangiogenic macro-
phages into cervical tumors is blocked pharmacologically, neutrophils
may replace them, thereby minimizing any therapeutic benefit. Thus,
in considering clinical strategies targeting tumor-promoting macro-
phages, it may prove that efficacy will be determined in part by the
capability of certain tissues (and/or tumor types) to affect resistance
through substitution, involving infiltration of compensatory neutrophils
in the context of macrophage suppression.
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Figure W1. Neutrophils do not inhibit monocyte infiltration into human tumor spheroids in vitro. Human tumor (cervical; HeLa or lung;
A549) spheroids were cocultured with either monocytes alone for 24 hours or neutrophils for 5 hours followed by monocytes for
24 hours. Flow cytometry of enzymatically dispersed spheroids showed that there were no significant differences (P = .252) in the level
of monocyte infiltration into spheroids when neutrophils were already present in these structures compared to when they were absent.
